Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli

With increased accessibility and tissue penetration, smaller antibody formats such as antibody fragments (Fab) and single chain variable fragments (scFv) show potential as effective and low-cost choices to full-length antibodies. These formats derived from the modular architecture of antibodies coul...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 13; no. 1; p. 14188
Main Authors: Tungekar, Aatir A., Ruddock, Lloyd W.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 30-08-2023
Nature Publishing Group
Nature Portfolio
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With increased accessibility and tissue penetration, smaller antibody formats such as antibody fragments (Fab) and single chain variable fragments (scFv) show potential as effective and low-cost choices to full-length antibodies. These formats derived from the modular architecture of antibodies could prove to be game changers for certain therapeutic and diagnostic applications. Microbial hosts have shown tremendous promise as production hosts for antibody fragment formats. However, low target protein yields coupled with the complexity of protein folding result in production limitations. Here, we report an alternative antibody fragment format ‘Fab H 3’ designed to overcome some key bottlenecks associated with the folding and production of Fabs. The Fab H 3 molecule is based on the Fab format with the constant domains replaced by engineered immunoglobulin G1 (IgG 1 ) C H 3 domains capable of heterodimerization based on the electrostatic steering approach. We show that this alternative antibody fragment format can be efficiently produced in the cytoplasm of E. coli using the catalyzed disulfide-bond formation system (CyDisCo) in a natively folded state with higher soluble yields than its Fab counterpart and a comparable binding affinity against the target antigen.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-41525-3